Open an account

Poniard Pharmaceuticals

PARD · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About PARD

Poniard Pharmaceuticals, Inc. is a bio-pharmaceutical company, which focuses on the development and commercialization of oncology products. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2011-12-30. The firm focuses on the development and commercialization of oncology products to impact the lives of people with cancer. The company develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The firm has offices in San Francisco, California; and Seattle, Washington in United States.

Employees
7
Headquarters
Seattle, Washington
Listed
Dec 30, 2011
Sector
Health Care
Industry
Biotechnology

PARD key statistics

Market cap
150
Price-earnings ratio
0.00
Dividend yield
—
Average volume
115
Volume
1
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0001
52 Week low
$0.00

Poniard Pharmaceuticals (PARD) at a glance

Poniard Pharmaceuticals (PARD) last traded at $0.0001, with a market cap of 150 and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 115 shares a day.

Over the past year Poniard Pharmaceuticals has ranged from $0.00 to $0.0001, and now sits 100% of the way up that range.

Poniard Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY10 it reported -$4.40 per share against an estimate of -$5.10.

PARD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 14.8% on average.

  1. Q1 FY09: reported -$15.20 per share against an estimate of -$15.39
  2. Q2 FY09: reported -$11.20 per share against an estimate of -$14.08
  3. Q3 FY09: reported -$11.60 per share against an estimate of -$12.00
  4. Q4 FY09: reported -$14.40 per share against an estimate of -$9.75
  5. Q1 FY10: reported -$11.60 per share against an estimate of -$9.44
  6. Q2 FY10: reported -$5.60 per share against an estimate of -$8.16
  7. Q3 FY10: reported -$5.20 per share against an estimate of -$6.39
  8. Q4 FY10: reported -$4.40 per share against an estimate of -$5.10

Similar companies

Companies in the same industry as Poniard Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.